SV2011004086A - Nuevos conjugados,su preparacion y su aplicacion terapeutica - Google Patents

Nuevos conjugados,su preparacion y su aplicacion terapeutica

Info

Publication number
SV2011004086A
SV2011004086A SV2011004086A SV2011004086A SV2011004086A SV 2011004086 A SV2011004086 A SV 2011004086A SV 2011004086 A SV2011004086 A SV 2011004086A SV 2011004086 A SV2011004086 A SV 2011004086A SV 2011004086 A SV2011004086 A SV 2011004086A
Authority
SV
El Salvador
Prior art keywords
group
rent
phenyle
diana
substitute
Prior art date
Application number
SV2011004086A
Other languages
English (en)
Inventor
Herve Bouchard
Marie-Priscille Brun
Alain Commercon
Jidong Zhang
Original Assignee
Sanofi Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41611078&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SV2011004086(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Sanofi Sa filed Critical Sanofi Sa
Publication of SV2011004086A publication Critical patent/SV2011004086A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D273/00—Heterocyclic compounds containing rings having nitrogen and oxygen atoms as the only ring hetero atoms, not provided for by groups C07D261/00 - C07D271/00
    • C07D273/08—Heterocyclic compounds containing rings having nitrogen and oxygen atoms as the only ring hetero atoms, not provided for by groups C07D261/00 - C07D271/00 having two nitrogen atoms and more than one oxygen atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D245/00—Heterocyclic compounds containing rings of more than seven members having two nitrogen atoms as the only ring hetero atoms
    • C07D245/04—Heterocyclic compounds containing rings of more than seven members having two nitrogen atoms as the only ring hetero atoms condensed with carbocyclic rings or ring systems
    • C07D245/06—Heterocyclic compounds containing rings of more than seven members having two nitrogen atoms as the only ring hetero atoms condensed with carbocyclic rings or ring systems condensed with one six-membered ring

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Peptides Or Proteins (AREA)
  • Saccharide Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

LA INVENCIÓN SE REFIERE A UN AGENTE DE SELECCIÓN DE LA DIANA AL QUE ESTÁ UNIDO AL MENOS UN DERIVADO DE CRIPTOFICINA DE LA FÓRMULA (1), EN LA QUE: R1 REPRESENTA UN ÁTOMO DE HALÓGENO Y R2 REPRESENTA UN GRUPO -OH, UN GRUPO ACILO DERIVADO DE UN AMINOÁCIDO AA O UN GRUPO ALCANOILOXI(C1-C4); O BIEN R1 Y R2 FORMAN CONJUNTAMENTE UN MOTIVO EPÓXIDO; AA INDICA UN AMINOÁCIDO NATURAL O NO NATURAL; R3 REPRESENTA UN GRUPO ALQUILO(C1-C6); R4 Y R5 REPRESENTAN LOS DOS H O FORMAN CONJUNTAMENTE UN DOBLE ENLACE CH=CH ENTRE C13 Y C14; R6 Y R7 REPRESENTAN INDEPENDIENTEMENTE UNO DE OTRO H O UN GRUPO ALQUILO(C1-C6); R8 Y R9 REPRESENTAN INDEPENDIENTEMENTE UNO DE OTRO H O UN GRUPO ALQUILO(CI-C6); RIO REPRESENTA AL MENOS UN SUSTITUYENTE DEL NÚCLEO FENILO ELEGIDO ENTRE: H, UN GRUPO OH, ALCOXI(CI-C4), UN ÁTOMO DE HALÓGENO O BIEN UN GRUPO -NH2, -NHALQUILO(C1-C6) O -N(ALQUILO(C1 -C6))2; R11 REPRESENTA AL MENOS UN SUSTITUYENTE DEL NÚCLEO FENILO ELEGIDO ENTRE H O UN GRUPO ALQUILO(C1-C4); ESTANDO UNIDOS EL AGENTE DE SELECCIÓN DE LA DIANA Y EL DERIVADO DE CRIPTOFICINA DE FORMA COVALENTE, SITUÁNDOSE LA UNIÓN EN POSICIÓN ORTO (O), META (M) O PARA (P) DEL NÚCLEO FENILO PORTADOR DEL MOTIVO CR1
SV2011004086A 2009-06-29 2011-12-15 Nuevos conjugados,su preparacion y su aplicacion terapeutica SV2011004086A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0903170A FR2947269B1 (fr) 2009-06-29 2009-06-29 Nouveaux composes anticancereux
FR0905651A FR2947271B1 (fr) 2009-06-29 2009-11-25 Nouveaux composes anticancereux

Publications (1)

Publication Number Publication Date
SV2011004086A true SV2011004086A (es) 2012-05-08

Family

ID=41611078

Family Applications (1)

Application Number Title Priority Date Filing Date
SV2011004086A SV2011004086A (es) 2009-06-29 2011-12-15 Nuevos conjugados,su preparacion y su aplicacion terapeutica

Country Status (30)

Country Link
US (1) US8952147B2 (es)
EP (1) EP2448929A1 (es)
JP (1) JP5746692B2 (es)
KR (1) KR101770584B1 (es)
CN (1) CN102482238B (es)
AR (1) AR078131A1 (es)
BR (1) BRPI1015131A2 (es)
CA (1) CA2766762C (es)
CL (1) CL2011003229A1 (es)
CO (1) CO6430462A2 (es)
CR (1) CR20110670A (es)
DO (1) DOP2011000376A (es)
EA (1) EA024627B1 (es)
EC (1) ECSP11011553A (es)
FR (2) FR2947269B1 (es)
HN (1) HN2011003414A (es)
IL (1) IL217208A (es)
MA (1) MA33465B1 (es)
MX (1) MX2011013764A (es)
MY (1) MY156684A (es)
NI (1) NI201100219A (es)
NZ (1) NZ597136A (es)
PE (1) PE20121031A1 (es)
SG (2) SG177419A1 (es)
SV (1) SV2011004086A (es)
TN (1) TN2011000636A1 (es)
TW (1) TW201110986A (es)
UY (1) UY32745A (es)
WO (1) WO2011001052A1 (es)
ZA (1) ZA201109537B (es)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL305084A (en) 2005-08-24 2023-10-01 Immunogen Inc A process for preparing purified drug compounds
LT2437790T (lt) 2009-06-03 2019-06-10 Immunogen, Inc. Konjugavimo būdai
NZ597050A (en) 2009-06-29 2014-02-28 Incyte Corp Pyrimidinones as pi3k inhibitors
US8759359B2 (en) 2009-12-18 2014-06-24 Incyte Corporation Substituted heteroaryl fused derivatives as PI3K inhibitors
EP2558463A1 (en) 2010-04-14 2013-02-20 Incyte Corporation Fused derivatives as i3 inhibitors
WO2011163195A1 (en) 2010-06-21 2011-12-29 Incyte Corporation Fused pyrrole derivatives as pi3k inhibitors
AR084366A1 (es) 2010-12-20 2013-05-08 Incyte Corp N-(1-(fenil sustituido)etil)-9h-purin-6-aminas como inhibidores de pi3k
US9108984B2 (en) 2011-03-14 2015-08-18 Incyte Corporation Substituted diamino-pyrimidine and diamino-pyridine derivatives as PI3K inhibitors
WO2012135009A1 (en) 2011-03-25 2012-10-04 Incyte Corporation Pyrimidine-4,6-diamine derivatives as pi3k inhibitors
KR20220009505A (ko) 2011-03-29 2022-01-24 이뮤노젠 아이엔씨 일-단계 방법에 의한 메이탄시노이드 항체 접합체의 제조
BR122019020716B1 (pt) 2011-09-02 2021-02-17 Incyte Holdings Corporation heterociclilaminas como inibidores de pi3k e composição farmacêutica que as compreende
AR090548A1 (es) 2012-04-02 2014-11-19 Incyte Corp Azaheterociclobencilaminas biciclicas como inhibidores de pi3k
SG11201502429YA (en) 2012-10-04 2015-04-29 Immunogen Inc Use of a pvdf membrane to purify cell-binding agent cytotoxic agent conjugates
CN105593238B (zh) 2013-07-11 2020-09-08 诺华股份有限公司 使用微生物转谷氨酰胺酶进行赖氨酸特异性化学酶法蛋白质修饰
US10077277B2 (en) 2014-06-11 2018-09-18 Incyte Corporation Bicyclic heteroarylaminoalkyl phenyl derivatives as PI3K inhibitors
CR20170111A (es) * 2014-09-03 2017-05-23 Immunogen Inc Derivados de benzodiazepina citotóxicos
GB201416960D0 (en) 2014-09-25 2014-11-12 Antikor Biopharma Ltd Biological materials and uses thereof
MD3262046T2 (ro) 2015-02-27 2021-03-31 Incyte Corp Săruri de inhibitori ai PI3K și procedee pentru prepararea lor
EP3069734A1 (en) * 2015-03-17 2016-09-21 Exiris S.r.l. Cryptophycin-based antibody-drug conjugates with novel self-immolative linkers
US9732097B2 (en) 2015-05-11 2017-08-15 Incyte Corporation Process for the synthesis of a phosphoinositide 3-kinase inhibitor
WO2016183063A1 (en) 2015-05-11 2016-11-17 Incyte Corporation Crystalline forms of a pi3k inhibitor
TWI660741B (zh) 2015-11-03 2019-06-01 財團法人工業技術研究院 抗體藥物複合物及其製造方法
TWI714661B (zh) * 2015-11-05 2021-01-01 法商賽諾菲公司 新穎念珠藻素化合物及接合物、其製備與其治療用途
WO2017136769A1 (en) * 2016-02-04 2017-08-10 Eisai R&D Management Co., Ltd. Peptide drug conjugates
WO2018178277A1 (en) 2017-03-29 2018-10-04 Avicenna Oncology Gmbh New targeted cytotoxic isocombretaquinoline derivatives and conjugates thereof
MA50764A (fr) 2017-05-10 2020-03-18 Sanofi Sa Linkers peptidiques et conjugués de cryptophycine, utiles en thérapie, et leur préparation
EP3665161B1 (en) 2017-08-09 2023-09-27 Helmholtz-Zentrum für Infektionsforschung GmbH New targeted cytotoxic ratjadone derivatives and conjugates thereof
CA3085600A1 (en) * 2017-12-22 2019-06-27 Cornell University 18f-labeled peptide ligands useful in pet and cerenkov luminescene imaging
CA3108289A1 (en) 2018-08-02 2020-02-06 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for treating facioscapulohumeral muscular dystrophy
US11911484B2 (en) 2018-08-02 2024-02-27 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for treating myotonic dystrophy
SG11202100934PA (en) 2018-08-02 2021-02-25 Dyne Therapeutics Inc Muscle targeting complexes and uses thereof for treating dystrophinopathies
US11168141B2 (en) 2018-08-02 2021-11-09 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for treating dystrophinopathies
FR3085952B1 (fr) 2018-09-17 2020-10-30 Centre Nat Rech Scient Conjugue anticorps-medicament comprenant des derives de quinoline
JP2022549971A (ja) 2019-09-30 2022-11-29 ザ・リージェンツ・オブ・ザ・ユニバーシティ・オブ・ミシガン クリプトフィシン抗がん剤の生体触媒合成
EP4046996A1 (en) 2021-02-19 2022-08-24 Universität Bielefeld Cryptophycin compounds and conjugates thereof
US11771776B2 (en) 2021-07-09 2023-10-03 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for treating dystrophinopathies
US11638761B2 (en) 2021-07-09 2023-05-02 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for treating Facioscapulohumeral muscular dystrophy
US11672872B2 (en) 2021-07-09 2023-06-13 Dyne Therapeutics, Inc. Anti-transferrin receptor antibody and uses thereof
US11633498B2 (en) 2021-07-09 2023-04-25 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for treating myotonic dystrophy
US11969475B2 (en) 2021-07-09 2024-04-30 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for treating facioscapulohumeral muscular dystrophy
WO2023057564A1 (en) 2021-10-07 2023-04-13 Sanofi IMIDAZO[4,5-c]QUINOLINE-4-AMINE COMPOUNDS AND CONJUGATES THEREOF, THEIR PREPARATION, AND THEIR THERAPEUTIC APPLICATIONS
US11931421B2 (en) 2022-04-15 2024-03-19 Dyne Therapeutics, Inc. Muscle targeting complexes and formulations for treating myotonic dystrophy

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2719170A (en) 1954-07-28 1955-09-27 Du Pont Alkyl omega-carboxyalkyl disulfides and their lower alkyl esters
US4981979A (en) 1987-09-10 1991-01-01 Neorx Corporation Immunoconjugates joined by thioether bonds having reduced toxicity and improved selectivity
EP0454726A4 (en) 1988-12-22 1991-11-27 Xoma Corporation Hindered linking agents and methods
US5208020A (en) 1989-10-25 1993-05-04 Immunogen Inc. Cytotoxic agents comprising maytansinoids and their therapeutic use
CA2056039A1 (en) 1991-01-22 1992-07-23 Philip L. Fuchs Carbacyclin analogs
JP4181632B2 (ja) 1995-03-07 2008-11-19 ユニバーシティ オブ ハワイ 新規合成クリプトフィシン類
CZ64599A3 (cs) * 1996-08-30 1999-10-13 Eli Lilly And Company Farmaceutické sloučeniny
CA2347246A1 (en) 1998-10-16 2000-04-27 James Abraham Aikins Stereoselective process for producing cryptophycins
WO2000034252A2 (en) 1998-12-07 2000-06-15 Eli Lilly And Company Process for the preparation of cryptophycin derivatives
EP1482972A4 (en) * 2001-11-20 2005-11-23 Seattle Genetics Inc TREATMENT OF IMMUNOLOGICAL DISORDERS USING ANTI-CD30 ANTIBODIES
US20040249130A1 (en) * 2002-06-18 2004-12-09 Martin Stanton Aptamer-toxin molecules and methods for using same
DE60336149D1 (de) 2002-08-16 2011-04-07 Immunogen Inc Vernetzer mit hoher reaktivität und löslichkeit und ihre verwendung bei der herstellung von konjugaten für die gezielte abgabe von kleinmolekularen arzneimitteln
US7230101B1 (en) 2002-08-28 2007-06-12 Gpc Biotech, Inc. Synthesis of methotrexate-containing heterodimeric molecules
HUE026914T2 (en) 2002-11-07 2016-08-29 Immunogen Inc Anti-CD33 antibodies and a method of treating acute myeloid leukemia
CN1956722A (zh) 2003-05-20 2007-05-02 伊缪诺金公司 含有新的美登素类的改进的细胞毒剂
CN103145844B (zh) 2003-07-21 2016-08-03 伊缪诺金公司 Ca6抗原特异性细胞毒性偶联物及其应用方法
US20050175619A1 (en) 2004-02-05 2005-08-11 Robert Duffy Methods of producing antibody conjugates
WO2005082023A2 (en) 2004-02-23 2005-09-09 Genentech, Inc. Heterocyclic self-immolative linkers and conjugates
TW200539855A (en) 2004-03-15 2005-12-16 Wyeth Corp Calicheamicin conjugates
GT200500283A (es) 2004-10-08 2006-05-08 Inmunoterapia de desordenes autoinmunes
EP1669358A1 (en) 2004-12-07 2006-06-14 Aventis Pharma S.A. Cytotoxic agents comprising new taxanes
PT1819359E (pt) * 2004-12-09 2015-05-28 Janssen Biotech Inc Imunoconjugados anti-integrina, métodos para a sua produção e sua utilização
MX2007007590A (es) 2004-12-22 2007-12-10 Ambrx Inc Composiciones que contienen, metodos que involucran y usos de aminoacidos no naturales y polipeptidos.
CA2600418A1 (en) 2005-03-07 2006-09-14 Archemix Corp. Stabilized aptamers to psma and their use as prostate cancer therapeutics
US7714016B2 (en) 2005-04-08 2010-05-11 Medarex, Inc. Cytotoxic compounds and conjugates with cleavable substrates
EP1813614B1 (en) 2006-01-25 2011-10-05 Sanofi Cytotoxic agents comprising new tomaymycin derivatives
EP1832577A1 (en) 2006-03-07 2007-09-12 Sanofi-Aventis Improved prodrugs of CC-1065 analogs
EP2010475A2 (en) 2006-04-27 2009-01-07 Intezyne Technologies Incorporated Heterofunctional poly(ethylene glycol) containing acid-labile amino protecting groups and uses thereof
EP1864682A1 (en) 2006-06-09 2007-12-12 Sanofi-Aventis Leptomycin derivatives
USRE47123E1 (en) 2006-07-18 2018-11-13 Sanofi EPHA2 receptor antagonist antibodies
EP1914242A1 (en) 2006-10-19 2008-04-23 Sanofi-Aventis Novel anti-CD38 antibodies for the treatment of cancer
EP3569251A1 (en) * 2007-06-25 2019-11-20 Endocyte, Inc. Conjugates containing hydrophilic spacer linkers
PL2019104T3 (pl) 2007-07-19 2014-03-31 Sanofi Sa Środki cytotoksyczne obejmujące nowe pochodne tomaymycyny i ich zastosowanie terapeutyczne
US8865875B2 (en) 2007-08-22 2014-10-21 Medarex, L.L.C. Site-specific attachment of drugs or other agents to engineered antibodies with C-terminal extensions
EP2276509B1 (en) 2008-04-11 2016-06-15 Seattle Genetics, Inc. Detection and tratment of pancreatic, ovarian and other cancers
BRPI0911442A2 (pt) 2008-04-30 2019-03-12 Immunogen, Inc. conjugados potentes e ligantes hidrofílicos
KR20210100223A (ko) 2008-04-30 2021-08-13 이뮤노젠 아이엔씨 가교제 및 그 용도
WO2010014812A2 (en) 2008-07-30 2010-02-04 The Research Foundation Of State University Of New York Peptide compositions and methods of use

Also Published As

Publication number Publication date
MA33465B1 (fr) 2012-07-03
DOP2011000376A (es) 2012-01-15
CO6430462A2 (es) 2012-04-30
CR20110670A (es) 2012-02-09
NI201100219A (es) 2012-05-23
UY32745A (es) 2011-01-31
KR20120101981A (ko) 2012-09-17
CL2011003229A1 (es) 2012-06-29
EP2448929A1 (fr) 2012-05-09
SG177419A1 (en) 2012-02-28
CA2766762C (fr) 2017-06-20
FR2947271B1 (fr) 2013-04-05
FR2947269A1 (fr) 2010-12-31
AU2010267917A1 (en) 2012-02-02
WO2011001052A1 (fr) 2011-01-06
US20120225089A1 (en) 2012-09-06
US8952147B2 (en) 2015-02-10
IL217208A (en) 2016-02-29
EA201270096A1 (ru) 2012-07-30
JP5746692B2 (ja) 2015-07-08
TW201110986A (en) 2011-04-01
MX2011013764A (es) 2012-05-22
EA024627B1 (ru) 2016-10-31
BRPI1015131A2 (pt) 2018-12-04
AU2010267917B2 (en) 2016-03-17
KR101770584B1 (ko) 2017-08-24
TN2011000636A1 (fr) 2013-05-24
FR2947269B1 (fr) 2013-01-18
MY156684A (en) 2016-03-15
SG10201607595WA (en) 2016-11-29
JP2012531459A (ja) 2012-12-10
CN102482238A (zh) 2012-05-30
CA2766762A1 (fr) 2011-01-06
IL217208A0 (en) 2012-03-01
AR078131A1 (es) 2011-10-19
PE20121031A1 (es) 2012-08-17
ECSP11011553A (es) 2012-01-31
CN102482238B (zh) 2015-08-12
FR2947271A1 (fr) 2010-12-31
NZ597136A (en) 2014-04-30
HN2011003414A (es) 2014-11-10
ZA201109537B (en) 2013-03-27

Similar Documents

Publication Publication Date Title
SV2011004086A (es) Nuevos conjugados,su preparacion y su aplicacion terapeutica
ES2624795T3 (es) Derivados de N-(heteroaril)-1-heteroaril-1H-indol-2-carboxamidas, su preparación y su aplicación en terapéutica
BRPI1011683B8 (pt) derivados de isoquinolina substituída, suas composições farmacêuticas e seus usos
HN2010001459A (es) Derivados de carboxamidas azabiciclicas, su preparacion y su preparacion en terapeutica.
PE20090362A1 (es) Derivados de piperidina/piperazina como moduladores de dgat
CO6210729A2 (es) Derivados de sulfonil-fenil-2h-[1,2,4]oxadiazol-5-ona procedimientos para su preparacion y su uso como agente farmaceutico
AR070352A1 (es) Derivado de pirrolopirimidina como inhibidor de la enzima pi3k, un procedimiento de elaboracion del compuesto, una composicion farmaceutica y un agente preventivo o terapeutico en base al compuesto.
AR066171A1 (es) Derivados de nicotinamida, composiciones farmaceuticas que los contienen, metodo de preparacion de los mismos y usos en la prevencion y/o tratamiento del cancer.
AR082111A1 (es) Furopiridinas o tienopiridinas condensadas, composiciones farmaceuticas que las contienen utiles para tratar trastornos psicoticos y del sistema nervioso central, y metodo de preparacion de las mismas
CU23761B7 (es) Nuevos derivados de diosmetina, su procedimiento de preparación y las composiciones farmacéuticas que los contienen
CO6362007A2 (es) Derivados de azaspiranil-alquilcarbamatos de heterociclos de 5 eslabones, su preparación y su aplicación en terapeútica
AR078776A1 (es) Derivados de (1,1,1,3,3,3-hexafluoro-2-hidroxipropan-2-il)-fenilo
AR082004A1 (es) Compuestos de fusion de piridina
CU20100157A7 (es) Nuevos derivados dihidroindolonas, su procedimiento de preparación y las composiciones farmacéuticas que los contienen
HN2012000217A (es) Compuestos derivados de amido espirociclicos y sales farmaceuticamente aceptable de los mismos.
AR066955A1 (es) Derivados de 7- alquinil -1,8- naftiridonas, su preparacion y su aplicacion en terapeutica
CO6290668A2 (es) Derivados de 1-oxo-1,2-dihidroisoquinolein-5-carboxamidas y de 4-oxo-3,4-dihifroquinazolina -8-carboxamidas su preparacion y su aplicacion en terapeutica
AR079267A1 (es) Derivados del tipo hexahidrociclopenta(b)pirrol, su procedimiento de preparacion y las composiciones farmaceuticas que los contienen
JO2851B1 (en) 3-benzofuranil-indole-2-one-3-substituted acetamidopiprazine derivatives, preparations thereof and therapeutic use thereof.
CU24134B1 (es) Nuevos derivados dihidro-oxazolobenzodiazepinonas, y las composiciones farmacéuticas que los contienen
AR080102A1 (es) Compuestos de aril-bencil-amina y su utilizacion en el tratamiento de trastornos mediados por las interacciones de los linfocitos
CR11494A (es) Nuevos derivados de acido 2-mercaptociclopentanocarboxilico, su procedimiento de preparacion y las composiciones farmaceuticas que los contienen
UY32895A (es) Derivados acetilénicos de 5-fenilpirazolopiridina, su preparación y su aplicación terapéutica
AR079266A1 (es) Derivados de azabiciclo[3.2.0]hept-6ilo, procedimiento de preparacion de los mismos, intermediarios de sintesis, composiciones farmaceuticas que los contienen y uso de los mismos para el tratamiento de enfermedades neurodegenerativas,tales como alzheimer.
AR079265A1 (es) Derivados de azabiciclo(3.1.0)hex-2-ilo, su procedimiento de preparacion y las composiciones farmaceuticas que los contienen